Effects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)

Sponsor
Trisakti University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05596383
Collaborator
(none)
112
1
2
10.3
10.9

Study Details

Study Description

Brief Summary

The aim of this intervention clinical study are: evaluation the effect of vitamin D supplementation on anti-oxidant status, inflammation, insulin resistance in patients type 2 diabetes mellitus.

The research question is how the effect of vitamin D supplementation for 3 and 6 months on anti-oxidant status, inflammation and insulin resistance in patients type 2 diabetes mellitus.

The main tasks participants will be asked to do:
  • interviews, filling the questionnaires, and giving informed consent after receiving an explanation by the researcher about the purpose of the research

  • taking blood for screening examination which includes examination of Serum Glutamic Pyruvic Transaminase (SGPT), albumin, creatinine and blood Ca.

  • participant who meet the inclusion and exclusion criteria, performed a physical examination (height and weight) and blood collection for examination 25(OH)D.

  • Subjects/participant with vitamin D deficiency and insufficiency will be included in randomization, two groups: the group that received vitamin D3 5,000 IU and the group that received a placebo. Vitamin D 5000 IU and placebo taken daily for 6 months.

  • Observations for 3 months and 6 months from the first time supplementation was given.

Treatments they'll be given:
  • During the study, the subject's clinical condition will be monitored.

  • Subject observations are monitored by telephone or google form to subject or their families

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Vitamin D 5000 IU
  • Dietary Supplement: Placebo
N/A

Detailed Description

Participant register: Patients type 2 DM aged > 18 years who went to the Community Health Centers Mampang were interviewed, filled out questionnaires, and gave informed consent.Interview by interviewers with at least high school education after being given training first by researchers.

The data is entered in a computer excel table by the researcher. Accuracy, completeness of registration data using the screening form.

Data that contains detailed descriptions of each variable used by the registry:
  • Gender: differences in the nature, form, and biological function of men and women that determine differences in reproduction, by interview using a questionnaire and identity card.

  • Duration DM: time from the first time being diagnosed DM until the start of the study, expressed in months

  • Subject's age: calculated from the time the study began with the date of birth listed on the identity card.

Standard Operating Procedures to address registry operations and analysis activities:
  • patient recruitment : Patients type 2 DM aged > 18 years who went to the Community Health Centers Mampang were interviewed.

  • data collection: using screening form

  • data management : using table excel computer

  • data analysis : using Statistical Package for the Social Sciences (SPSS) versi 23

  • report for adverse event: using form adverse event Sample size assessment : formula for hypothesis testing the mean difference of two groups Plan for missing data : back up data Statistical analysis plan to address the primary and secondary objectives: normality test (kolmogorov Smirnov), test statistic (T independent test or Mann Whitney test, Anova test)

Study Design

Study Type:
Interventional
Anticipated Enrollment :
112 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study was divided into two groups, the intervention group and the control group. The intervention group received vitamin D 5000 IU/day for 6 months and the control group received a placebo (contains microcrystalline, calcium carbonate, sodium starch) for 6 monthsThe study was divided into two groups, the intervention group and the control group. The intervention group received vitamin D 5000 IU/day for 6 months and the control group received a placebo (contains microcrystalline, calcium carbonate, sodium starch) for 6 months
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
THE EFFECT OF VITAMIN D SUPPLEMENTATION ON IMPROVING PANCREAS BETA CELL FUNCTION IN TYPE 2 DIABETES MELLITUS: STUDY OF SOD,IL-6,PDX-1 EXPRESSION, and INSULIN RESISTANCE
Actual Study Start Date :
Feb 12, 2022
Anticipated Primary Completion Date :
Dec 23, 2022
Anticipated Study Completion Date :
Dec 23, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Vitamin D, dosage form chewable tablet, dosage 5000 IU, frequency every day, duration six months

Dietary Supplement: Vitamin D 5000 IU
Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet

Placebo Comparator: control group

Placebo (microcrystalline,calcium carbonate, sodium starch), dosage form chewable tablet, frequency every day, duration six month

Dietary Supplement: Placebo
Placebo

Outcome Measures

Primary Outcome Measures

  1. level of Superoxide Dismutase (SOD) [Change from Baseline at 3 and 6 months]

    SOD

  2. Interleukin-6 (IL-6) [Change from Baseline at 3 and 6 months]

    IL-6 in monocyte: % (method immunoflowcytometry);

  3. pancreatic and duodenal homeobox 1(PDX-1) expression [Change from Baseline at 3 and 6 months]

    PDX-1 expression : ct (method polymerase chain reaction /PCR);

  4. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) [Change from Baseline at 3 and 6 months]

    HOMA-IR : formula (fasting insulin (μIU/mL) x fasting blood glucose (mg/dL)/405

Secondary Outcome Measures

  1. vitamin D level [Change from Baseline at 3 and 6 months]

    Vitamin D: ng/mL;

  2. (hemoglobin glycate) HbA1C [Change from Baseline at 3 and 6 months]

    HbA1c: % ;

  3. fasting blood glucose [Change from Baseline at 3 and 6 months]

    Fasting blood glucose: mg/dL ;

  4. fasting insulin [Change from Baseline at 3 and 6 months]

    Fasting insulin: μIU/mL

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • male and female, aged > 18 years

  • period of DM ≤ 3 years

  • using a single anti-diabetic drug (monotherapy)

  • HbA1c > 6,5%

Exclusion Criteria:
  • receive insulin therapy

  • kidney disease, liver disease

  • pregnant and lactating women

  • allergy history

  • hypercalcemia history

  • consumption of vitamin D in the last 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Community Health Centers Kecamatan Mampang Prapatan Jakarta DKI Jakarta Indonesia 12720

Sponsors and Collaborators

  • Trisakti University

Investigators

  • Principal Investigator: Alvina Alvina, Universitas Trisakti

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
dr Alvina Alvina,SpPK, clinical pathology specialist, Trisakti University
ClinicalTrials.gov Identifier:
NCT05596383
Other Study ID Numbers:
  • Trisaktipatklin
First Posted:
Oct 27, 2022
Last Update Posted:
Oct 27, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2022